SecProbe.io

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 15, 2025

David Ayanoglou
Chief Financial Officer
Healthcare Triangle, Inc.
7901 Stoneridge Drive, Suite 220
Pleasanton, CA 94588

 Re: Healthcare Triangle, Inc.
 Registration Statement on Form S-1
 Filed April 1, 2025
 File No. 333-286331
Dear David Ayanoglou:

 We have conducted a limited review of your registration statement and
have the
following comments.

 Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Cover page

1. We note your references in your prospectus to an "alternative cashless
exercise" of the
 Series B Warrants. The term "cashless exercise" is generally understood
to allow a
 warrant holder to exercise a warrant without paying cash for the
exercise price and
 reducing the number of shares receivable by the holder by an amount
equal in value to
 the aggregate exercise price the holder would otherwise pay to exercise
the warrants.
 In cashless exercises, it is expected that the warrant holder receives
fewer shares than
 they would if they opted to pay the exercise price in cash. Please
clarify your
 disclosure throughout the prospectus by removing the references to
"alternative
 cashless exercise" and exclusively using the term "zero exercise price"
or another
 appropriate term that conveys that, in addition to the company receiving
no cash upon
 the "alternative cashless exercise," the warrant holders would be
entitled to receive
 April 15, 2025
Page 2

 more shares than they would under the cash exercise terms.
2. Please revise your cover page disclosure to highlight that the
alternative cashless
 exercise provision would allow a Series B warrant holder to receive 3
shares of
 common stock without having to make any exercise payment, and provide a
 materially complete discussion of the impact of such exercise on
existing
 shareholders. Explain that as a result you do not expect to receive any
cash proceeds
 from the exercise of the Series B warrants because, if true, it is
highly unlikely that a
 warrant holder would wish to pay an exercise price to receive one share
when they
 could choose the alternative cashless exercise option and pay no money
to receive 3
 shares.
Risk Factors, page 5

3. With reference to the disclosure on pages 8-9, please add a new risk
factor to address
 potential dilution from the reset provision that could adjust upward the
number of
 common shares underlying the Series B Warrants. The risk factor should
disclose the
 maximum number of shares that may be issuable upon exercise of the
warrants.
 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

 Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

 Please contact Aliya Ishmukhamedova at 202-551-7519 or Matthew Crispino
at 202-
551-3456 with any other questions.

 Sincerely,

 Division of
Corporation Finance
 Office of
Technology
cc: Jeffrey Wofford, Esq.
</TEXT>
</DOCUMENT>